Protalix BioTherapeutics Inc. (NYSE:PLX) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Alexandra Schuman - LifeSci Advisors, IR Dror Bashan - President & CEO Eyal Rubin - SVP & CFO Conference Call Participants John Vandermosten - Zacks Small Cap Research Operator Good morning, ladies and gentlemen, and welcome to the Protalix First Quarter 2022 Financial and Business Results Conference Call. [Operator Instructions] I do reminder, this conference call is being recorded. I wil ...

OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 001-33357 FORM 10-Q (Commission file number) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Delaware __65-0643773__ (State or other jurisdiction of incorporation or organization) Securities registered pursuant to ...

Protalix BioTherapeutics Inc. (NYSE:PLX) Q4 2021 Earnings Conference Call March 31, 2022 8:30 AM ET Company Participants Dror Bashan - President, Chief Executive Officer Eyal Rubin - Senior Vice President, Chief Financial Officer Charles Padala - LifeSci Advisors Conference Call Participants John Vandermosten - Zacks Small Cap Research Operator Good morning ladies and gentlemen and welcome to Protalix BioTherapeutics’ full year 2021 earnings conference call. At this time, all participants are in a listen ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION | | | Page | | --- | --- | --- | | | PART I | | | | Cautionary Statement Regarding Forward-Looking Statements and Risk Factors Summary | 1 | | Item 1. | Business | 2 | | Item 1A. | Risk Factors | 32 | | Item 1B. | Unresolved Staff Comments | 58 | | Item 2. | Properties | 58 | | Item 3. | Legal Proceedings | 58 | | Item 4. | Mine Safety Disclosures | 58 | | | PART II | | | Item 5. | Market for Registrant's Common Equity, Related Stockholder M ...

Start Time: 08:30 January 1, 0000 8:48 AM ET Protalix BioTherapeutics, Inc. (NYSE:PLX) Q3 2021 Earnings Conference Call November 15, 2021, 08:30 AM ET Company Participants Dror Bashan - President and CEO Eyal Rubin - SVP and CFO Chuck Padala - LifeSci Advisors, IR Conference Call Participants Boobalan Pachaiyappan - H.C. Wainwright John Vandermosten - Zacks Operator Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics Third Quarter 2021 Financial Results and Business Update Confer ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 001-33357 (Commission file number) PROTALIX BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware __65-0643773__ (State or other jurisdiction of incorpor ...

Protalix BioTherapeutics, Inc. (NYSE:PLX) Q2 2021 Earnings Conference Call August 16, 2021 8:30 AM ET Company Participants David Holmes - LifeSci Advisors, Investor Relations Dror Bashan - President & Chief Executive Officer Eyal Rubin - Senior Vice President & Chief Financial Officer Conference Call Participants Boobalan Pachaiyappan - H.C. Wainwright John Vandermosten - Zacks Investments Operator Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics Second Quarter 2021 Financial ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 001-33357 (Commission file number) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading Symbol(s) | registered | | -- ...

Protalix BioTherapeutics, Inc. (NYSE:PLX) Q1 2021 Earnings Conference Call May 14, 2021 8:30 AM ET Company Participants Chuck Padala - LifeSci Advisors Dror Bashan - President & Chief Executive Officer Eyal Rubin - Senior Vice President & Chief Financial Officer Conference Call Participants Boobalan Pachaiyappan - H.C. Wainwright John Vandermosten - Zacks Investments Operator Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics First Quarter 2021 Financial and Business Results Con ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 001-33357 (Commission file number) PROTALIX BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware __65-06437 ...